Table 2.
Studies for peritoneal carcinomatosis with cytoreductive surgery
| Ref. | Patient No. | Treatment group(s) | Intraperitoneal regimen | Systemic regimen | Outcomes | ||
| Bonnot et al[30], 2018 | 277 | CRS alone vs CRS + HIPEC | 1 | 1 | CRS Alone Median OS: 12.1 mo | CRS + HIPEC Median OS: 12.1 mo | |
| Yang et al[31], 2011 | 68 | CRS alone vs CRS + HIPEC | Cisplatin and MMC | - | CRS Alone Median OS: 6.5 mo | CRS + HIPEC Median OS: 11.0 mo | |
| Glehen et al[32], 2010 | 159 | CRS with PIC (HIPEC or EPIC) | Variable | - | Median OS: 9.2 mo | ||
| Rudloff et al[33], 2014 | 16 | CRS/HIPEC/SC vs SC alone | Oxaliplatin | FOLFOXIRI | SC Alone 4.3 mo | CRS/HIPEC/SC Median OS: 11.3 mo | |
| Canbay et al[34], 2014 | 194 | NA systemic and IP chemo, then CRS and HIPEC if responsive | Docetaxel and cisplatin | Oral S-1 | 78.3% had negative cytology and underwent CRS and HIPEC | ||
| No response (no CRS or HIPEC) Median OS: 7.5 mo | Response (CRS with HIPEC) Median OS: 15.8 mo | ||||||
| Yonemura et al[38], 2017 | 105 | NLHIPEC → CRS or NLHIPEC → NIPS → CRS | Docetaxel and cisplatin | Oral S-1, IV docetaxel and cisplatin | NLHIPEC + CRS Median OS: 14.1 mo PCI: 14.2 → 11.8 | NLHIPEC + NIPS + CRS Median OS: 19.2 mo PCI: 14.8 → 9.9 | |
1
Abstract only, agents used not included. CRS: Cytoreductive surgery; HIPEC: Hyperthermic intraperitoneal chemotherapy; OS: Overall survival; MMC: Mitomycin C; PIC: Perioperative chemotherapy; EPIC: Early postoperative intraperitoneal chemotherapy; SC: Systemic chemotherapy; NA: Neoadjuvant; IP: Intraperitoneal; NLHIPEC: Neoadjuvant laparoscopic HIPEC; NIPS: Neoadjuvant intraperitoneal and systemic chemotherapy; PCI: Peritoneal carcinomatosis index.